European Medicines Agency Revises Nitrosamine Impurity Guidance

The European Medicines Agency (EMA) has updated its guidance on nitrosamine impurities in medicines, reflecting new policies and recommendations. This revision, agreed upon by the CHMP, includes higher acceptable intake limits for nitrosamine impurities in certain medicines with treatment durations under 10 years. This aims to provide clearer regulatory expectations for pharmaceutical manufacturers.